Fig. 2.

Forest plots of vascular occlusive events, OS, and MMR in patients with Ph+ ALL treated with new-generation TKIs vs. imatinib (adapted from [40]). MMR, major molecular response; TKI, tyrosine kinase inhibitor; OS, overall survival. Diamonds reflect the summary effect for each TKI. The summary effect size was derived from the following trials: Bosutinib: BELA (NCT00574873); Dasa­tinib: SWOG-S0325 (NCT00070499), START-R (NCT00103844), DASISION (NCT00481247), NordCML006 (NCT­00852566), NCT00320190; Nilotinib: RE-NICE (NCT01400074), ENESTnd (NCT­00471497), ENESTcmr (NCT00760877); Ponatinib: EPIC (NCT01650805). No forest plot contains all available 10 trials because for each analysis (overall survival, major molecular response, and vascular occlusive events), at least one study did not report the event of interest. 95% CI, 95% confidence interval.